Pharmacologic management of Arrhythmias

Texas Heart Institute Journal

Volumn 38, Issue 4, 2011, Pages 344-349

  Ganjehei, Leila ^a   Massumi, Ali ^a   Nazeri, Alireza ^a   Razavi, Mehdi ^a  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; CALCIUM CHANNEL L TYPE; CIMETIDINE; COTRIMOXAZOLE; DISOPYRAMIDE; DOFETILIDE; DRONEDARONE; FLECAINIDE; HYDROCHLOROTHIAZIDE; INSULIN; KETOCONAZOLE; METFORMIN; POTASSIUM CHANNEL; PROCAINAMIDE; PROCHLORPERAZINE; PROPAFENONE; SODIUM CHANNEL; SOTALOL; VERAPAMIL; WARFARIN;

ACUTE LIVER FAILURE; AGRANULOCYTOSIS; ANTICHOLINERGIC EFFECT; ASTHMA; BLURRED VISION; BRADYCARDIA; BRONCHOSPASM; CONFUSION; CONGESTIVE HEART FAILURE; CONSTIPATION; DIZZINESS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG PROTEIN BINDING; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GLAUCOMA; HALLUCINATION; HEART ARRHYTHMIA; HEART ATRIOVENTRICULAR NODE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE REFRACTORY PERIOD; HEART PROARRHYTHMIA; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; LIVER TOXICITY; LUNG TOXICITY; MORTALITY; NAUSEA; PARESTHESIA; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PR INTERVAL; PR PROLONGATION; QRS COMPLEX; QRS PROLONGATION; QT PROLONGATION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SINUS BRADYCARDIA; TACHYCARDIA; TASTE DISORDER; THYROID DISEASE; TORSADE DES POINTES; URINE RETENTION; XEROSTOMIA;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; HEART CONDUCTION SYSTEM; HUMANS; POTASSIUM CHANNEL BLOCKERS; SODIUM CHANNEL BLOCKERS; TREATMENT OUTCOME;

EID: 80051752436     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Vaughan Williams EM. Classifying antiarrhythmic actions: by facts or speculation. J Clin Pharmacol 1992;32(11):964-77.
2. Brunton LL, Chabner B, Knollmann B, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill; 2011.
3. Harvey RA, Champe PC, Finkel R, Cubeddu LX, Clarke MA, editors. Lippincott's illustrated reviews: pharmacology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2008.
4. Fornieles-Perez H, Montoya-Garcia M, Levine PA, Sanz O. Documentation of acute rise in ventricular capture thresholds associated with flecainide acetate. Pacing Clin Electrophysiol 2002;25(5):871-2.
5. Bond R, Augustine D, Walker S. Iatrogenic flecainide toxicity. Heart 2010;96(24):2048-9.
6. Brazil E, Bodiwala GG, Bouch DC. Fatal flecainide intoxication. J Accid Emerg Med 1998;15(6):423-5.
7. Devin R, Garrett P, Anstey C. Managing cardiovascular collapse in severe flecainide overdose without recourse to extracorporeal therapy. Emerg Med Australas 2007;19(2):155-9.
8. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 1989;321(6):406-12.
9. Zipes DP, Jalife J, editors. Cardiac electrophysiology: from cell to bedside. 5th ed. Philadelphia: Saunders Elsevier; 2009.
10. Abitbol H, Califano JE, Abate C, Beilis P, Castellanos H. Use of flecainide acetate in the treatment of premature ventricular contractions. Am Heart J 1983;105(2):227-30.
11. Ferlini M, Colli AM, Bonanomi C, Salvini L, Galli MA, Salice P, et al. Flecainide as first-line treatment for supraventricular tachycardia in newborns. J Cardiovasc Med (Hagerstown) 2009;10(5):372-5.
12. Khan IA. Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol 2003;87(2-3):121-8.
13. Couto N, Ferreira M, Reis E. Neutropenia and cutaneous lesions secondary to propafenone. Eur J Dermatol 2009;19(4): 365-7.
14. Galasso PJ, Stanton MS, Vogel H. Propafenone-induced peripheral neuropathy. Mayo Clin Proc 1995;70(5):469-72.
15. Miwa LJ, Jolson HM. Propafenone associated agranulocytosis. Pacing Clin Electrophysiol 1992;15(4 Pt 1):387-90.
16. Zervakis J, Graham BG, Schiffman SS. Taste effects of lingual application of cardiovascular medications. Physiol Behav 2000;68(3):405-13.
17. Boriani G, Martignani C, Biffi M, Capucci A, Branzi A. Oral loading with propafenone for conversion of recent-onset atrial fibrillation: a review on in-hospital treatment. Drugs 2002;62(3):415-23.
18. Hill MR, Gotz VP, Harman E, McLeod I, Hendeles L. Evaluation of the asthmogenicity of propafenone, a new antiarrhythmic drug. Comparison of spirometry with methacholine challenge. Chest 1986;90(5):698-702.
19. Conrad ME, Cumbie WG, Thrasher DR, Carpenter JT. Agranulocytosis associated with disopyramide therapy. JAMA 1978;240(17):1857-8.
20. Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S. Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release. Am J Physiol 1993; 265(2 Pt 1):C337-42.
21. Reynolds RM, Walker JD. Hypoglycaemia induced by disopyramide in a patient with type 2 diabetes mellitus. Diabet Med 2001;18(12):1009-10.
22. Ehrlich JR, Nattel S. Novel approaches for pharmacological management of atrial fibrillation. Drugs 2009;69(7):757-74.
23. Connolly SJ. Evidence-based analysis of amiodarone efficacy and safety. Circulation 1999;100(19):2025-34.
24. Davy JM, Herold M, Hoglund C, Timmermans A, Alings A, Radzik D, et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J 2008;156(3):527. e1-9.
25. Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N, Hohnloser SH. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J 2003;24(16):1481-7.
26. Piccini JP, Hasselblad V, Peterson ED, Washam JB, Califf RM, Kong DF. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation [published erratum appears in J Am Coll Cardiol 2010;55(19):2185].
27. J Am Coll Cardiol 2009;54 (12):1089-95.
28. Duray GZ, Torp-Pedersen C, Connolly SJ, Hohnloser SH. Effects of dronedarone on clinical outcomes in patients with lone atrial f ibrillation: pooled post hoc analysis from the ATHENA/EURIDIS/ADONIS studies. J Cardiovasc Electrophysiol 2011 Feb 2 [Epub ahead of print].